Cipher Pharmaceuticals Inc. - Third Quarter 2026 Financial Results Call - DEFI TECHNOLOGIES INC

Explicit Guidance:

• No specific financial guidance (revenue, earnings, margins, capex, etc.) for Q4 2026 or full-year 2026 was provided in the transcript.
• The company disclosed that public drug plan funding for Epurus became effective August 17 in British Columbia, August 27 in Quebec, and October 1 in Alberta, expecting this to "continue contributing to market share growth over time."
• Management expects the results of Health Canada's review for Netroba to be released "likely in the first quarter of 2027."
• The arbitration award grants CIFR a 15% royalty on net sales of Zorica LD (Absorica LD) in Canada, beginning January 1, 2026, and running through the end of 2040.

Business-Segment Outlook:

• Natroba (U.S. Head Lice/Scabies): Sequential revenue increased 14% in Q3 2026 (vs. 4% decline previously), though impacted by reduced Medicaid covered lives. Future growth is expected to be driven by expanding beyond Medicaid into commercial payers, direct-to-patient, and retail pharmacy channels via expanded marketing campaigns.
• Natroba (International): Health Canada has accepted the new drug submission for review; management anticipates results in Q1 2027. The product targets unmet needs for head lice and scabies in Canada and Rest of World (ROW) due to resistance in existing treatments.
• Epurus (Canada): Expected to benefit from expanded public drug plan coverage in key jurisdictions (BC, Quebec, Alberta), which should drive further market share growth and address a previously inaccessible patient population. Management views the product as the leading isotretinoin product in Canada and believes it has potential to perform strongly in other global territories with similar market structures.
• Epurus (International): Active pursuit of out-licensing opportunities in non-North American markets; engagement of a consulting firm to strengthen these efforts and broaden the pipeline of interested parties.
• Product Portfolio: Continued focus on acquiring or in-licensing complementary products that can be commercialized through existing U.S. and Canadian infrastructure.

Market and Competitive Outlook:

• U.S. Head Lice/Scabies: Management believes Netroba fulfills a critical unmet need compared to permethrin-resistant strains. While OTC adoption is common, the company aims to educate consumers and prescribers on Netroba's superiority, targeting patients who have failed permethrin treatments.
• Canada Acne Market: Epurus saw market share increase to 48.7% (up 1.6 percentage points from June 2026); continued growth is anticipated as public funding expands access.
• Competitive Positioning: CIFR remains optimistic about capturing market share from ineffective generic alternatives (e.g., permethrin) both domestically and internationally, particularly in markets where resistance is prevalent.

Macro / Industry Outlook:

• Regulatory: No specific macro-economic guidance provided, but the successful court affirmation of the arbitration award (NY federal court) is viewed as a significant win securing IP rights and future royalty streams.
• Supply Chain/Operations: No specific macro indicators (rates, inflation) mentioned, but the company highlights "operational efficiencies" gained during the year as a driver for expense reductions.

Strategic Initiatives:

• M&A and Business Development: Three-pronged strategy active: 1) Acquisition/in-licensing of complementary products (focus on expanding U.S. volume and UK infrastructure utilization, with some Canadian opportunities); 2) Out-licensing of Netroba and Epurus outside North America; 3) Company acquisitions for strategic scale.
• Board Enhancements: Appointment of Rajiv De Silva (Sept 21) expected to strengthen M&A execution capabilities.
• Capital Deployment: Management is evaluating a Substantial Issuer Bid (SIB) as a more effective mechanism for share repurchases compared to the National Instrument 62-104 (NCIB) program, which they view as restrictive.
• Timeline: Management expects to execute a transaction "in the short term" but declined to provide specific dates to avoid price leverage by vendors.

Risks and Headwinds to Outlook:

• Medicaid Volumes: Continued risk of revenue reduction for Netroba if Medicaid programs further reduce covered lives or implement "step-through" requirements (prioritizing cheaper alternatives) at the state level.
• Execution Uncertainty: Business development timelines are variable; opportunities may not materialize despite active pursuit.
• Competitive Adoption: In head lice markets, low consumer research and ingrained habits regarding OTC products pose a barrier to Netroba adoption.
• Valuation Leverage: The company explicitly noted that providing specific timelines for M&A could give vendors leverage on pricing.

Management Tone on the Future:

• Confidence Level: Management expressed "optimism" regarding the success of business development activities and the potential upside of the royalty stream (2040) and Canadian expansion.
• Hedges: Repeated caveats that M&A timelines vary and "opportunities may or may not come to realization."
• Financial Stance: High confidence in the company's cash-generative nature, debt-free status, and profitability (81% gross margin, 58% adjusted EBITDA margin YTD).

Miscellaneous:

• Arbitration Award: Received $5.7 million in October 2026 related to the award; 15% royalty on Canadian Absorica LD sales starts Jan 1, 2026, through 2040.
• Cash Position: Ended Q3 2026 with $15.3 million in cash, increasing to approximately $20 million post-quarter-end collections; maintains $65 million undrawn facility plus $25 million accordion feature.
• Licensing Discussions: Ongoing discussions with Sun Pharmaceuticals regarding Absorica extension and evaluating proposals from other generic outfits.